Nonalcoholic Steatohepatitis Diagnostics Market Trends

  • Report ID: 4718
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT
  1. Market Definition
    1. Definition
    2. Market Segmentation
    3. Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
    3. Secondary Research
  4. Executive Summary – Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market
  5. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  6. Decarbonization Strategy and Carbon Credit Benefit for Market Players
  7. Regulatory and Standards Landscape
  8. Industry Risk Analysis
  9. Global Economic Outlook: Challenges for Global Recovery and its Impact on Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market
  10. Technology Advancement in Nonalcoholic Steatohepatitis (NASH) Diagnostics Market
  11. Industry Supply Chain Analysis
  12. Analysis on Diagnostic Models
  13. Analysis on Recent Development or Trends
  14. Analysis on Types of Imaging Biomarkers
  15. Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2023-2036
      1. By Type
        1. Serums Biomarkers, 2023-2036F (USD Million)
        2. Hepatic Fibrosis Biomarkers, 2023-2036F (USD Million)
        3. Oxidative Stress Biomarkers, 2023-2036F (USD Million)
        4. Apoptosis Biomarkers, 2023-2036F (USD Million)
        5. Others, 2023-2036F (USD Million)
      2. By End User
        1. Pharma & CRO Industry, 2023-2036F (USD Million)
        2. Hospitals, 2023-2036 (USD Million)
        3. Academic Research Institutes, 2023-2036F (USD Million)
        4. Others, 2023-2036 (USD Million)
      3. By Region
        1. North America, 2023-2036 (USD Million)
        2. Europe, 2023-2036 (USD Million)
        3. Asia Pacific, 2023-2036 (USD Million)
        4. Latin America, 2023-2036 (USD Million)
        5. Middle East & Africa, 2023-2036 (USD Million)
  16. North America Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2023-2036
      1. By Type
        1. Serums Biomarkers, 2023-2036F (USD Million)
        2. Hepatic Fibrosis Biomarkers, 2023-2036F (USD Million)
        3. Oxidative Stress Biomarkers, 2023-2036F (USD Million)
        4. Apoptosis Biomarkers, 2023-2036F (USD Million)
        5. Others, 2023-2036F (USD Million)
      2. By End User
        1. Pharma & CRO Industry, 2023-2036F (USD Million)
        2. Hospitals, 2023-2036 (USD Million)
        3. Academic Research Institutes, 2023-2036F (USD Million)
        4. Others, 2023-2036 (USD Million)
      3. By Country
        1. US, 2023-2036F (USD Million)
        2. Canada, 2023-2036 (USD Million)
  17. Europe Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2023-2036
      1. By Type
      2. By End User
      3. By Country
        1. UK, 2023-2036F (USD Million)
        2. Germany, 2023-2036 (USD Million)
        3. Italy, 2023-2036F (USD Million)
        4. France, 2023-2036 (USD Million)
        5. Spain, 2023-2036F (USD Million)
        6. Russia, 2023-2036 (USD Million)
        7. Netherlands, 2023-2036F (USD Million)
  18. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2023-2036
      1. By Type
      2. By End User
      3. By Country
        1. China, 2023-2036F (USD Million)
        2. India, 2023-2036 (USD Million)
        3. Japan, 2023-2036F (USD Million)
        4. Australia, 2023-2036 (USD Million)
        5. South Korea, 2023-2036F (USD Million)
        6. Singapore, 2023-2036 (USD Million)
        7. Rest of Asia Pacific, 2023-2036 (USD Million)
  19. Latin America Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2023-2036
      1. By Type
      2. By End User
      3. By Country
        1. Brazil, 2023-2036F (USD Million)
        2. Argentina, 2023-2036 (USD Million)
        3. Mexico, 2023-2036F (USD Million)
        4. Rest of Latin America, 2023-2036 (USD Million)
  20. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2023-2036
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2023-2036
      1. By Type
      2. By End User
      3. By Country
        1. GCC, 2023-2036F (USD Million)
        2. Israel, 2023-2036 (USD Million)
        3. South Africa, 2023-2036F (USD Million)
        4. Rest of the Middle East and Africa, 2023-2036 (USD Million)
  21. Competitive Landscape
    1. Company Market Share Analysis
    2. Company Profiles
      1. Echosens
      2. Prometheus Laboratories
      3. Genfit
      4. Siemens Medical Solutions USA, Inc.
      5. BioPredictive
      6. Quest Diagnostics Incorporated.
      7. Meridian Bioscience, Inc.
      8. Laboratory Corporation of America Holdings
      9. Bristol-Myers Squibb Company
      10. One Way Liver SL
      11. Other Major Players
    3. End User Analysis

Nonalcoholic Steatohepatitis Diagnostics Market Trends

Growth Drivers

  • Increasing Prevalence of NASH and NAFLD - NAFLD includes nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH), diagnosed when there is evidence of inflammatory activity and hepatocyte injury in steatotic liver tissue. According to a National Center for Biotechnology Information (NCBI) study conducted in 2020, one-quarter of the global population is estimated to have nonalcoholic fatty liver disease (NAFLD). In addition, the incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by up to 56% in the next ten years. NAFLD is already the fastest-growing cause of hepatocellular carcinoma (HCC) in the USA, France, and the UK. Globally, the prevalence of NAFLD-related HCC is likely to increase concomitantly with the growing obesity epidemic, which is also a reason for the higher demands for NASH diagnostics biomarkers globally.
  • Rising Demand for Providing Novel Diagnostic Tools - Various non-invasive tests are being widely adopted by healthcare professionals to diagnose Nonalcoholic Steatohepatitis (NASH), propelling the market growth. Non-invasive tests are used for predicting the severity of fibrosis in NAFLD patients. These include both serologic tests and imaging techniques. The serologic tests include AST to Platelet Ratio Index (APRI) score, Fibrosis-4 (Fib-4) calculator, and NAFLD fibrosis score (NFS). A score of greater than 1 with APRI less than 0.676 with NFS and greater than 2.67 with Fib-4 predicts the presence of advanced fibrosis. In contrast, an NFS of less than -1.455 and a Fib-4 score of less than 1.3 suggests a low risk for advanced fibrosis. These advanced test techniques are growing the market.
  • Growing Adoption of Serum Markers and Score System for NAFLD and NASH Diagnosis - In November, a study undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE), an initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium (FNIH), confirmed that NIS4 technology reveals a unique performance in recognizing patients with at-risk Non-Alcoholic Steatohepatitis (NASH), and provided evidence that it had the best results of the five blood-based biomarker panels which were evaluated in this study, for the diagnosis of fibrosis stage≥ 2.
  • Increasing Funding and Collaborations for NASH Detection Techniques - A new project involving a consortium that is part of the Innovative Medicines Initiative (IMI), the world’s most significant public-private partnership of its kind, aims to tackle the glaring lack of diagnostic tools by seeking reliable, measurable medical signs, or biomarkers, that indicate the presence of NASH. The project, co-led by Pfizer, is known as LITMUS, or “Liver Investigation: Testing Marker Utility in Steatohepatitis.” LITMUS is coordinated by Professor Quentin Anstee at Newcastle University in the U.K. and is part of IMI, which is funded jointly by the European Commission and the European pharmaceutical industry, known by its acronym, EFPIA.
  • Rising Trends of Unhealthy Diet and Lack of Physical Activity- The prevalence of NAFLD rises in parallel with the increasing prevalence of obesity, metabolic syndrome (MetS), and T2D. According to the WHO, overweight and obesity are now rapidly on the rise in low and middle-income countries, particularly in urban settings. A vast majority of overweight or obese children live in developing countries, where the rate of increase has been more than 30% higher than that of developed countries.

 Challenges

  • Stringent Regulations for Biomarkers Approval by Regulatory Bodies- In-vitro diagnostics are regulated by the FDA and Japan Pharmaceuticals and Medical Devices Agency (PMDA) and will soon have a formal regulatory framework in Europe. However, when the FDA approves novel targeted therapies, EMA, and PMDA, the companion diagnostic test required to select patients receiving the therapy is considered for approval concurrently with the therapy. Therefore, negatively affecting the market growth.
  • Absence of NAFLD/NASH from Health Policies Focused on Obesity
  • Poor Demand in the Underdeveloped Countries

Nonalcoholic Steatohepatitis Diagnostics Market: Key Insights

Base Year

2022

Forecast Year

2023-2033

CAGR

23.8%

Base Year Market Size (2022)

USD 983.8 million

Forecast Year Market Size (2033)

USD 10,253.0 million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America, and Brazil)
  • Asia-Pacific (Singapore, Japan, China, India, South Korea, Australia, Rest of Asia-Pacific)
  • Europe (Netherlands, U.K., Germany, France, Italy, Spain, Russia, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Base Year

2024

Forecast Year

2025-2037

CAGR

23.6%

Base Year Market Size (2024)

USD 1.52 billion

Forecast Year Market Size (2037)

USD 24.15 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4718
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of nonalcoholic steatohepatitis diagnostics is assessed at USD 1.81 billion.

The nonalcoholic steatohepatitis diagnostics market size was valued at USD 1.52 billion in 2024 and is set to reach USD 24.15 billion by the end of 2037, registering around 23.6% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of NASH and NAFLD and rising demand for providing novel diagnostic tools will boost the market growth.

Asia Pacific is predicted to hold largest industry share by 2037, due to increasing burden of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the region.

The major players in the market include Echosen, Prometheus Laboratories, Genfit, Siemens Medical Solutions USA, Inc., BioPredictive, Quest Diagnostics Incorporated., Meridian Bioscience, Inc., Laboratory Corporation of America Holdings, Bristol-Myers Squibb Company, One Way Liver SL.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample